Baseline and 12-month MIC and myocardial T2* in the placebo (n = 4) and amlodipine arm (n = 8) in patients with a baseline T2* <20 ms (MIC > 1.16mg/g). The mild gray area represents patients at the lowest risk of developing heart failure, the light gray area represents mild to moderate risk, and the dark gray area represents MIC levels at which there is significant risk for cardiovascular complications.⁴ MIC and T2* can be converted using the formula [Fe] = 45.0 × (T2*)^−1.22.²⁰ A T2* of 10 ms represents a MIC of 2.71 mg/g, whereas a T2* of 20 ms corresponds to a MIC of 1.16 mg/g (data are presented in MIC [A] and T2* values [B]). No patient in the placebo group shifted from their original risk assessment, whereas 4 of 8 patients changed from severe to moderate risk or from moderate to low risk. All patients in the amlodipine arm reduced their baseline MIC values with a significant change at 12 months (2.9 mg/g [95% CI, 1.6-5.9] vs 2.1 [95% CI, 1.0-4.5], P = .008); in the placebo arm, no significant changes in MIC were observed (2.8 mg/g [95% CI, 1.7-3.8] vs 2.7 [95% CI, 1.7-4.1], P = .88).